Aptus Pharma Ltd
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2011 | Mar 2016 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Mar 2030 (P) | |
|---|---|---|---|---|---|---|---|
| Number of Products (SKUs) count ・Standalone data |
|
||||||
| Number of Therapeutic Segments count ・Standalone data |
|||||||
| Top 5 Contract Manufacturer Concentration % of purchases ・Standalone data |
|||||||
| Central Warehouse Area sq ft ・Standalone data |
|||||||
| Number of Distributors count ・Standalone data |
|||||||
| Number of Doctors Reached count ・Standalone data |
|||||||
| Prescriptions per Day count/day ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Intimation of Investor Presentation under Regulation 30 of SEBI (LODR) Regulations, 2015
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Intimation of Earnings Call for the quarter and half year ended September 30, 2026
-
Financial Results For The Half Year Ended 30Th September,2026
- Board approved H1 FY27 results on 20 Oct 2026; revenue ₹48.92 crore, PAT ₹5.07 crore.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 20.10.2026 Along With Financial Results For Half Year Ended 30Th September, 2026
- Board approved H1 FY2026-27 unaudited results: revenue ₹48.92 crore, PAT ₹5.07 crore.
-
Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Half Year Ended On September 30, 2026 And Closure Of Trading Window
- Board meets 20 Oct 2026 to approve H1 FY2026-27 unaudited results; trading window closed from 1 Oct.
Business Profile[1]
Aptus Pharma Limited is a Gujarat-based marketer and distributor of pharmaceutical formulations, operating in an asset-light model through contract manufacturing partners. It offers a diverse portfolio of 194 products across multiple therapeutic categories.